{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:42:21Z","timestamp":1794606141066,"version":"4.9.1"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:p>\n                    To investigate the prevalence and prognostic significance of programmed death ligand-1 (PD-L1) expression and CD8\n                    <jats:sup>+<\/jats:sup>\n                    tumor-infiltrating lymphocytes (TILs) in gynecologic carcinosarcoma, 81 cases (68 uterine, 12 ovarian, and 1 fallopian tube) were immunostained with PD-L1 and CD8 using tissue microarrays (3\u2009mm core diameter) from intratumoral areas with the highest TILs. Tumor proportion score (TPS) \u22651% and combined positive score (CPS) \u22651 were considered positive for PD-L1. CD8\n                    <jats:sup>+<\/jats:sup>\n                    TILs were counted in each core, and CD8\n                    <jats:sup>+<\/jats:sup>\n                    TIL density (CD8TILD) was calculated. Cases were classified as CD8\n                    <jats:sup>Neg<\/jats:sup>\n                    (&lt;1.4\/mm\n                    <jats:sup>2<\/jats:sup>\n                    CD8TILD), CD8\n                    <jats:sup>Pos<\/jats:sup>\n                    (\u22651.4\/mm\n                    <jats:sup>2<\/jats:sup>\n                    CD8TILD) and CD8\n                    <jats:sup>HIGH<\/jats:sup>\n                    (\u226514\/mm\n                    <jats:sup>2<\/jats:sup>\n                    CD8TILD) and grouped into 4 tumor immune microenvironment (TIME) groups: (1) PD-L-1\n                    <jats:sup>Pos<\/jats:sup>\n                    \/CD8\n                    <jats:sup>Pos<\/jats:sup>\n                    , (2) PD-L1\n                    <jats:sup>Neg<\/jats:sup>\n                    \/CD8\n                    <jats:sup>Neg<\/jats:sup>\n                    , (3) PD-L1\n                    <jats:sup>Pos<\/jats:sup>\n                    \/CD8\n                    <jats:sup>Neg<\/jats:sup>\n                    , and (4) PD-L1\n                    <jats:sup>Neg<\/jats:sup>\n                    \/CD8\n                    <jats:sup>Pos<\/jats:sup>\n                    . PD-L1 expression by TPS and CPS was detected in 19.8% and 39.6% cases, respectively. Kaplan-Meier curves with log-rank analysis showed that higher density of CD8\n                    <jats:sup>+<\/jats:sup>\n                    TILs were associated with longer overall survival (OS) (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.05 for CD8\n                    <jats:sup>Pos<\/jats:sup>\n                    and\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.014 for CD8\n                    <jats:sup>HIGH<\/jats:sup>\n                    ), and CD8\n                    <jats:sup>HIGH<\/jats:sup>\n                    status was associated with longer OS irrespective of tumor stage (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.045, hazard ratio: 0.11, 95% confidence interval: 0.014\u20130.951). Thirty-three percent of patients belonged to TIME group 1. PD-L1 expression and TIME groups were not associated with OS or progression-free survival. We found that high density of CD8\n                    <jats:sup>+<\/jats:sup>\n                    TILs is an independent indicator of better OS. In 33% cases PD-L1 expression is associated with increased CD8\n                    <jats:sup>+<\/jats:sup>\n                    TILs (\u201cacquired immune evasion\u201d pattern of PD-L1 expression), hence they may benefit from anti PD-1\/PD-L1 therapy. PD-L1 expression alone and TIME groups do not affect survival in gynecologic carcinosarcoma.\n                  <\/jats:p>","DOI":"10.1097\/pgp.0000000000000890","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T12:00:42Z","timestamp":1653998442000},"page":"364-375","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Programmed Death Ligand 1 (PD-L1) Expression and CD8+ Tumor-infiltrating Lymphocyte-based Tumor Immune Microenvironment Classification in Gynecologic Carcinosarcoma: Prognostic Impact and Implications for Therapy"],"prefix":"10.1097","volume":"42","author":[{"given":"Jeffrey","family":"Ordner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Gutierrez Amezcua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratibha S.","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"R1-20250802","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","article-title":"Natural innate and adaptive immunity to cancer","volume":"29","author":"Vesely","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"R2-20250802","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"R3-20250802","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"R4-20250802","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.2147\/OTT.S190168","article-title":"Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis","volume":"12","author":"Yang","year":"2019","journal-title":"Onco Targets Ther"},{"key":"R5-20250802","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10549-019-05371-0","article-title":"Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis","volume":"178","author":"Huang","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"R6-20250802","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.humpath.2015.09.006","article-title":"Prognostic significance of PD-L1 and PD-L2 in breast cancer","volume":"47","author":"Baptista","year":"2016","journal-title":"Hum Pathol"},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12865-018-0285-5","article-title":"Correlate tumor mutation burden with immune signatures in human cancers","volume":"20","author":"Wang","year":"2019","journal-title":"BMC Immunol"},{"key":"R8-20250802","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"R9-20250802","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"R10-20250802","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1073\/pnas.0611618104","article-title":"CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma","volume":"104","author":"Sharma","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R11-20250802","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1158\/1078-0432.CCR-14-1905","article-title":"Stromal CD8+ T-cell density\u2014a promising supplement to TNM staging in non-small cell lung cancer","volume":"21","author":"Donnem","year":"2015","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"R12-20250802","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","article-title":"Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer","volume":"29","author":"Mahmoud","year":"2011","journal-title":"J Clin Oncol"},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41416-020-0813-y","article-title":"Identification and validation of an immunogenic subtype of gastric cancer with abundant intratumoural CD103+CD8+ T cells conferring favourable prognosis","volume":"122","author":"Li","year":"2020","journal-title":"Br J Cancer"},{"key":"R14-20250802","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R15-20250802","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1158\/1078-0432.CCR-15-0244","article-title":"Differential expression of immune-regualtory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade","volume":"21","author":"Taube","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R16-20250802","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"R17-20250802","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/bjc.2015.101","article-title":"IFN-\u03b3 from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer","volume":"112","author":"Abiko","year":"2015","journal-title":"Br J Cancer"},{"key":"R18-20250802","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/cas.13424","article-title":"PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer","volume":"109","author":"Mimura","year":"2018","journal-title":"Cancer Sci"},{"key":"R19-20250802","doi-asserted-by":"crossref","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Co-localization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"R20-20250802","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"R21-20250802","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1158\/1078-0432.CCR-15-2834","article-title":"Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration","volume":"22","author":"Ock","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R22-20250802","doi-asserted-by":"crossref","first-page":"697","DOI":"10.7150\/jca.28494","article-title":"Multi-omics perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration in urothelial cancer","volume":"10","author":"Chen","year":"2019","journal-title":"J Cancer"},{"key":"R23-20250802","doi-asserted-by":"crossref","first-page":"26356","DOI":"10.18632\/oncotarget.15465","article-title":"Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients","volume":"8","author":"Koh","year":"2017","journal-title":"Oncotarget"},{"key":"R24-20250802","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1002\/cam4.2580","article-title":"The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes","volume":"8","author":"Chen","year":"2019","journal-title":"Cancer Med"},{"key":"R25-20250802","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/tbj.13112","article-title":"PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER-2 positive invasive breast cancer","volume":"24","author":"Hou","year":"2018","journal-title":"Breast J"},{"key":"R26-20250802","doi-asserted-by":"crossref","first-page":"80443","DOI":"10.18632\/oncotarget.19045","article-title":"Tumor PD-L1 status and CD8+ tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer","volume":"8","author":"De Meulenaere","year":"2017","journal-title":"Oncotarget"},{"key":"R27-20250802","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/modpathol.2016.221","article-title":"Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer","volume":"30","author":"Enwere","year":"2017","journal-title":"Mod Pathol"},{"key":"R28-20250802","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1097\/PAS.0000000000001503","article-title":"PD-L1 expression and CD8+ tumor-infiltrating lymphocytes in different types of tubo-ovarian carcinoma and their prognostic value in high-grade serous Carcinoma","volume":"44","author":"Chen","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R32-20250802","first-page":"485","article-title":"Primary peritoneal carcinosarcoma arising from the Douglas pouch: a case report","volume":"9","author":"Koyanagi","year":"2018","journal-title":"Mol Clin Oncol"},{"key":"R33-20250802","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ygyno.2021.05.003","article-title":"Uterine carcinosarcomas: from pathology to practice","volume":"162","author":"Toboni","year":"2021","journal-title":"Gynecol Oncol"},{"key":"R34-20250802","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s12253-020-00829-9","article-title":"TCGA classification of endometrial cancer: the place of carcinosarcoma","volume":"26","author":"Travaglino","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"R35-20250802","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1038\/s41467-019-12985-x","article-title":"Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma","volume":"10","author":"Gotoh","year":"2019","journal-title":"Nat Commun"},{"key":"R36-20250802","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/AOG.0b013e318176157c","article-title":"Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior","volume":"112","author":"Bansal","year":"2008","journal-title":"Obstet Gynecol"},{"key":"R37-20250802","first-page":"1","article-title":"Prognostic value of the TCGA molecular classification in uterine carcinosarcoma","author":"Travaglino","year":"2021","journal-title":"Int J Gynecol Obstet"},{"key":"R38-20250802","doi-asserted-by":"crossref","first-page":"e173290","DOI":"10.1001\/jamaoncol.2017.3290","article-title":"Ovarian tumor tissue analysis (OTTA) consortium. Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer","volume":"3","author":"Goode","year":"2017","journal-title":"JAMA Oncol"},{"key":"R39-20250802","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccell.2017.02.010","article-title":"Integrated molecular characterization of uterine carcinosarcoma","volume":"31","author":"Cherniack","year":"2017","journal-title":"Cancer Cell"},{"key":"R40-20250802","doi-asserted-by":"crossref","first-page":"153028","DOI":"10.1016\/j.prp.2020.153028","article-title":"An immunohistochemical analysis of CD3, PD-L1, and CTLA-4 expression in carcinosarcomas of the gynecological tract and their metastases","volume":"216","author":"Karpathiou","year":"2020","journal-title":"Pathol Res Pract"},{"key":"R41-20250802","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/PGP.0000000000000752","article-title":"PD-L1 and mismatch repair status in uterine carcinosarcomas","volume":"40","author":"Jenkins","year":"2021","journal-title":"Int J Gynecol Pathol"},{"key":"R42-20250802","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/PAI.0000000000000457","article-title":"PD-L1 expression in carcinosarcomas of gynecological tract: a potentially actionable biomarker","volume":"26","author":"Pinto","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R43-20250802","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/ijc.30537","article-title":"Distinct molecular landscapes between endometrioid and non-endometrioid uterine carcinomas","volume":"140","author":"Jones","year":"2017","journal-title":"Int J Cancer"},{"key":"R44-20250802","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00428-020-02954-x","article-title":"Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components","volume":"478","author":"Lien","year":"2021","journal-title":"Virchows Arch"},{"key":"R45-20250802","doi-asserted-by":"crossref","first-page":"570623","DOI":"10.3389\/fonc.2021.570623","article-title":"Mismatch repair deficiency and microsatellite instability in triple-negative breast cancer: a retrospective study of 440 patients","volume":"11","author":"Ren","year":"2021","journal-title":"Front Oncol"},{"issue":"suppl","key":"R46-20250802","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1158\/1538-7445.AM2021-626","article-title":"The neoantigen and immune landscape of epithelial mesenchymal transition (EMT) low and high score serous ovarian cancers","volume":"81","author":"Hur","year":"2021","journal-title":"Cancer Res"},{"key":"R47-20250802","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17588359211039899","article-title":"Immune checkpoint inhibitors in ovarian cancer: where do we stand?","volume":"13","author":"Leary","year":"2021","journal-title":"Ther Adv Med Oncol"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000890","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:01:33Z","timestamp":1754161293000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000890","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,16]]}}}